Tromethamine
FDA-approved product (solution, injection), marketed as Tham, Tromethamine.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBL- WHO therapeutic group
- Solutions affecting the electrolyte balance; Other i.v. solution additives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Tromethamine, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA7.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli8.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae4.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis9.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Tromethamine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Micafungin SodiumExisting use: Candidiasis52.4% AI-predicted activityagainst E. coli50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm52.3% AI-predicted activityagainst E. coli50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- Ponatinib HydrochlorideExisting use: Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Lymphoid leukemia and 1 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- FinerenoneExisting use: Cardiovascular disease, Chronic kidney disease, Type 2 diabetes mellitus52.2% AI-predicted activityagainst E. coli50+ registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma52.0% AI-predicted activityagainst E. coli50+ registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more52.0% AI-predicted activityagainst E. coli22 registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis51.9% AI-predicted activityagainst E. coli50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia51.8% AI-predicted activityagainst E. coli4 registered studies
- TucatinibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 6 more51.6% AI-predicted activityagainst E. coli50+ registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more51.4% AI-predicted activityagainst E. coli14 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effect of Spinal Ketorolac on Mechanical Hypersensitivity After a Total Hip Replacement
NCT00621530 · start 2008-03
Registered record
- Registry ID
- NCT00621530
- Conditions
- Hip Arthroplasty
- Interventions
- ketorolac tromethamine opthalmic solution; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2008-03
- Completion
- 2013-06
- Enrolment
- 62
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHip ArthroplastyInterventionketorolac tromethamine opthalmic solution; placeboPhasePhase 2Registry statusTerminatedStudy to Assess the PK of Ketorolac Tromethamine Intranasal and to Assess the Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine
NCT01363089 · start 2007-01
Registered record
- Registry ID
- NCT01363089
- Conditions
- Assess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine
- Interventions
- Ketorolac tromethamine; Oxymetazoline hydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-01
- Completion
- 2008-02
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAssess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac TromethamineInterventionKetorolac tromethamine; Oxymetazoline hydrochloridePhasePhase 1Registry statusCompletedSafety and Efficacy of Multiple Doses of Intranasal Ketorolac in Postoperative Pain Following Major Abdominal Surgery
NCT00266786 · start 2005-12
Registered record
- Registry ID
- NCT00266786
- Conditions
- Postoperative Pain
- Interventions
- Intranasal Ketorolac Tromethamine; Intranasal Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2005-12
- Completion
- Not recorded
- Enrolment
- 321
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostoperative PainInterventionIntranasal Ketorolac Tromethamine; Intranasal PlaceboPhasePhase 3Registry statusCompletedA Single-dose Study of Intranasal Ketorolac in the Treatment of Pain Secondary to Dental Impaction Surgery
NCT01356225 · start 2004-02
Registered record
- Registry ID
- NCT01356225
- Conditions
- Pain; Dental Impaction
- Interventions
- Ketorolac tromethamine; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-02
- Completion
- Not recorded
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPain; Dental ImpactionInterventionKetorolac tromethamine; PlaceboPhasePhase 2Registry statusCompletedThe Balloon Project for Birth Induction
NCT01255839 · start 2002-12
Registered record
- Registry ID
- NCT01255839
- Conditions
- Induction Time; Apgar Score; Admission to Neonatal Unit; Vaginal Delivery; Caesarean Section
- Interventions
- Double Balloon; Minprostin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-12
- Completion
- 2010-12
- Enrolment
- 825
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInduction Time; Apgar Score; Admission to Neonatal Unit; Vaginal Delivery +1 moreInterventionDouble Balloon; MinprostinPhasePhase 4Registry statusCompleted